Venetoclax-treated t(11;14) patients with gain/amp(1q21) may also fare worse, since this cytogenetic aberration is associated with elevated MCL-1 levels and offers myeloma cells an alternative antiapoptotic mechanism independent of venetoclax effect (40,41). This evidence concerns the gene MCL1 and plasma cell myeloma.